Internal medicine, Neuroendocrine tumors, Pathology, Cancer research and Oncology are his primary areas of study. His Internal medicine study incorporates themes from Gastroenterology, Endocrinology and Surgery. His studies in Neuroendocrine tumors integrate themes in fields like Clinical trial, Carcinoid tumors, Everolimus, Sunitinib and Octreotide.
The Pathology study combines topics in areas such as Colorectal cancer, Gastrointestinal tract and Endocrine system. His studies deal with areas such as Exome sequencing, Exome, Immunohistochemistry, Germline mutation and DNA repair as well as Cancer research. His Oncology study combines topics from a wide range of disciplines, such as Adrenal gland and Metastasis.
His primary areas of investigation include Internal medicine, Neuroendocrine tumors, Oncology, Gastroenterology and In patient. As part of one scientific family, he deals mainly with the area of Internal medicine, narrowing it down to issues related to the Surgery, and often Clinical trial. His biological study spans a wide range of topics, including Sunitinib, Octreotide, Cancer research and Everolimus.
He combines subjects such as Lung and Sirolimus with his study of Everolimus. His work in Oncology covers topics such as Chemotherapy which are related to areas like Irinotecan. His Gastroenterology research incorporates elements of Neutropenia, Confidence interval and Adenocarcinoma.
Matthew H. Kulke focuses on Internal medicine, Neuroendocrine tumors, Oncology, In patient and Gastroenterology. Carcinoid syndrome, Everolimus, Quality of life, Progression-free survival and Hazard ratio are the core of his Internal medicine study. His Progression-free survival research includes themes of Survival analysis and Phases of clinical research.
Matthew H. Kulke has researched Neuroendocrine tumors in several fields, including Cancer, Clinical endpoint, Adverse effect and Octreotide. His Oncology research integrates issues from Treatment outcome, Rectum and Cohort. His research in Colorectal cancer focuses on subjects like Microsatellite instability, which are connected to Cancer research.
Matthew H. Kulke mainly focuses on Internal medicine, Neuroendocrine tumors, Oncology, Gastroenterology and Clinical endpoint. His Internal medicine research incorporates themes from Endocrinology and Surgery. His study in Neuroendocrine tumors is interdisciplinary in nature, drawing from both Progressive disease, Clinical trial, Phases of clinical research and Octreotide.
His Oncology study combines topics in areas such as Adrenal gland, Pathology, Gastrointestinal tract, Distant metastasis and Advanced disease. His research in Pathology tackles topics such as Small intestine which are related to areas like Cancer research. His research ties Carcinoma and Gastroenterology together.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
Jonathan Strosberg;G. El-Haddad;Edward Wolin;A. Hendifar.
The New England Journal of Medicine (2017)
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.
James C. Yao;Nicola Fazio;Simron Singh;Roberto Buzzoni.
The Lancet (2016)
Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial
James C. Yao;Catherine Lombard-Bohas;Eric Baudin;Larry K. Kvols.
Journal of Clinical Oncology (2010)
Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors
Matthew H. Kulke;Heinz Josef Lenz;Neal J. Meropol;James Posey.
Journal of Clinical Oncology (2008)
NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas.
Matthew H. Kulke;Lowell B. Anthony;David L. Bushnell;Wouter W. de Herder.
Phase II Study of Temozolomide and Thalidomide in Patients With Metastatic Neuroendocrine Tumors
Matthew H. Kulke;Keith Stuart;Peter C. Enzinger;David P. Ryan.
Journal of Clinical Oncology (2006)
Consensus guidelines for the management and treatment of neuroendocrine tumors.
Pamela L. Kunz;Diane Reidy-Lagunes;Lowell B. Anthony;Erin M. Bertino.
Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing.
Jin Li;Lilin Wang;Harvey Mamon;Matthew H Kulke.
Nature Medicine (2008)
Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set
David S. Klimstra;Irvin R. Modlin;N. Volkan Adsay;Runjan Chetty.
The American Journal of Surgical Pathology (2010)
O6-Methylguanine DNA Methyltransferase Deficiency and Response to Temozolomide-Based Therapy in Patients with Neuroendocrine Tumors
Matthew H. Kulke;Jason L. Hornick;Christine Frauenhoffer;Susanne Hooshmand.
Clinical Cancer Research (2009)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: